Preclinical studies have demonstrated the efficacy of targeting LAG-3 in combination with immune checkpoint receptors in EOC, and Phase I/II development of a LAG-3 monoclonal antibody is currently being investigated in pancreatic, breast, melanoma, and other solid tumors, including ovarian cancer (32). The gene discussed is LAG3; the disease is melanoma.